Research progress on the relationship between gut microbiota and primary liver cancer

doi:10.3877/cma.j.issn.1674-0793.2025.05.012

Abstract

Abstract:

Primary liver cancer (PLC) is a prevalent malignancy globally characterized by poor prognosis. Recent research has focused on the association between the gut microbiota and PLC. The gut microbiota interacts with the liver via the gut-liver axis; its dysbiosis can affect hepatic metabolism and immune function, thereby contributing to the initiation and progression of PLC. This review will detail in the relationship between the gut microbiota and PLC in terms of pathogenesis, diagnosis, treatment, and prevention, beginning with an overview of the gut microbiota’s composition and function, as well as an overview of PLC. The aim is to provide novel insights and theoretical foundations for the prevention and treatment of PLC.

Key words: Gastrointestinal microbiome, Liver neoplasms, Gut microbiota, Relationship

Jihong Fei, Sijia Liu, Yunjian Liu. Research progress on the relationship between gut microbiota and primary liver cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(05): 347-350.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2025.05.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2025/V19/I05/347

Figures/Tables 2

References 35

［1］	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
［2］	Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma[J]. Nature Reviews Disease Primers Nat Rev Dis Primers, 2016, 2(1): 16018.
［3］	Silva CAC, Fidelle M, Almonte AA, et al. Gut microbiota-related biomarkers in immuno-oncology[J]. Annu Rev Pharmacol Toxicol, 2025, 65(1): 333-354.
［4］	Okumura R, Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis[J]. Exp Mol Med, 2017, 49(5): e338.
［5］	Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota[J]. World J Gastroenterol, 2015, 21(29): 8787-8803.
［6］	Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate[J]. Nature, 2011, 469(7331): 543-547.
［7］	Gu X, Sun R, Chen L, et al. Neutral ceramidase mediates nonalcoholic steatohepatitis by regulating monounsaturated fatty acids and gut IgA+ B cells[J]. Hepatology, 2021, 73(3): 901-919.
［8］	Valdes AM, Walter J, Segal E, et al. Role of the gut microbiota in nutrition and health[J]. BMJ, 2018, 361: k2179.
［9］	Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159(3): 849-863.
［10］	Wells JM, Brummer RJ, Derrien M, et al. Homeostasis of the gut barrier and potential biomarkers[J]. Am J Physiol Gastrointest Liver Physiol, 2017, 312(3): G171-G193.
［11］	Wang R, Tang R, Li B, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cell Mol Immunol, 2021, 18(1): 4-17.
［12］	Brunnemann KD, Hecht SS, Hoffmann D. N-nitrosamines: environmental occurrence, in vivo formation and metabolism[J]. J Toxicol Clin Toxicol, 1982, 19(6–7): 661-688.
［13］	Yu LX, Yan HX, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J]. Hepatology, 2010, 52(4): 1322-1333.
［14］	Pallozzi M, De Gaetano V, Di Tommaso N, et al. Role of gut microbial metabolites in the pathogenesis of primary liver cancers[J]. Nutrients, 2024, 16(14): 2372.
［15］	Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539.
［16］	Li X, Ramadori P, Pfister D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021, 21(9): 541-557.
［17］	Wang X, Fang Y, Liang W, et al. Gut-liver translocation of pathogen klebsiella pneumoniae promotes hepatocellular carcinoma in mice[J]. Nat Microbiol, 2025, 10(1): 169-184.
［18］	Schneider KM, Mohs A, Gui W, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment[J]. Nat Commun, 2022, 13: 3964.
［19］	Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut, 2019, 68(6): 1014-1023.
［20］	Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science, 2016, 352(6285): 565-569.
［21］	Kazmierczak-Siedlecka K, Skonieczna-Żydecka K, Hupp T, et al. Next-generation probiotics-do they open new therapeutic strategies for cancer patients?[J/OL]. Gut Microbes, 2022, 14(1): 2035659.
［22］	Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J]. J Hepatol, 2012, 57(4): 803-812.
［23］	Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J]. Proc Natl Acad Sci U S A, 2016, 113(9): E1306-E1315.
［24］	Carvalho PLA, Anarade MER, Trindade LM, et al. Prophylactic and therapeutic supplementation using fructo-oligosaccharide improves the intestinal homeostasis after mucositis induced by 5-fluorouracil[J]. Biomed Pharmacother, 2021, 133: 111012.
［25］	Wan X, Guo H, Liana Y, et al. The physiological functions and pharmaceutical applications of inulin: A review[J]. Carbohydr Polym, 2020, 246: 116589.
［26］	Monteagudo-Mera A, Rastall RA, GIBSON GR, et al. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health[J]. Appl Microbiol Biotechnol, 2019, 103(16): 6463-6472.
［27］	Markowiak P, Ślizewska K. Effects of probiotics, prebiotics, and synbiotics on human health[J]. Nutrients, 2017, 9(9): 1021.
［28］	Bajaj JS, NG SC, Schnabl B. Promises of microbiome-based therapies[J]. J Hepatol, 2022, 76(6): 1379-1391.
［29］	Smits LP, Bouter KE, De Vos WM, et al. Therapeutic potential of fecal microbiota transplantation[J]. Gastroenterology, 2013, 145(5): 946-953.
［30］	Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients[J]. Science, 2021, 371(6529): 602-609.
［31］	Defilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant[J]. N Engl J Med, 2019, 381(21): 2043-2050.
［32］	Zellmer C, Sater MRA, Huntley MH, et al. Shiga toxin-producing Escherichia coli transmission via fecal microbiota transplant[J]. Clin Infect Dis, 2021, 72(11): e876-e880.
［33］	Messenheimer DJ, Jensen SM, Afentoulis ME, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40[J]. Clin Cancer Res, 2017, 23(20): 6165-6177.
［34］	Purohit HJ. Gut-bioreactor and human health in future[J]. Indian J Microbiol, 2018, 58(1): 3-7.
［35］	Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response[J]. Gastroenterology, 2018, 155(1): 33-37, e6.

[1]	Sizhuo Wang, Xiaoxin Duan, Long Chen, Shengli Dong. Causal effect of gut microbiome， blood metabolites and gastric cancer： A mediated Mendelian randomization study in East Asian populations [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(03): 163-168.
[2]	Xidong Chen, Shaochuang Wang, Hewei Zhao, Shuo Wang, Weidong Yuan. Study on risk factors for acute hepatic function deterioration after conventional TACE in elderly patients with BCLC stage B hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 689-692.
[3]	Feng Shen, Kui Wang, Jianwei Liu. The current status，challenges，and development of laparoscopic liver cancer surgery in China [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 237-240.
[4]	Jianqian Cai, Xinyu Bi, Bowen Xu. Challenges and strategies in laparoscopic hepatectomy for liver cancer patients in China [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 241-244.
[5]	Zhankui Wang, Zhiyuan Chen, Wenhui Sun, Qingling Yang, Xiaobin Yang. A predictive study on the preoperative immune inflammatory index and the level of AFU for the early recurrence of hepatocellular carcinoma patients after interventional treatment [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 247-250.
[6]	Haitao Sheng, Mingrui Dou, Junjie Wang, Xiaolong Xiu, Jianmao Yang, Changcheng Dong. Application of individualized hepatic segmentation based on CT three-dimensional visualization technology in anatomical hepatectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(03): 258-261.
[7]	Xiaowei Chang, Yu Cai, Zhiyong Zhao, Wei Zhang. Efficacy and safety analysis of high intensity focused ultrasound ablation combined with hepatic arterial chemoembolization in the treatment of primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 56-59.
[8]	Yong Lan, Jing Liu, Zhiqi Yang, Lang Wu, Xiaochun Sha, Minghao Li. Research progress in gut microbes in the incidence and development of pancreatitis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(03): 481-486.
[9]	Hepatobiliary and Pancreatic Disease Prevention and Control Specialty Society of Chinese Prevention Medicine Association, Hepato‐Oncology Branch of China International Exchange and Promotive Association for Medical and Healthcare. Chinese expert consensus on precision guidance technology in diagnosis and treatment of liver tumors（2024 edition） [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 145-157.
[10]	Yani Gou, Qunbin Shen, Li Zhang, Jiajia Lu. Interaction mechanisms, challenges, and intervention strategies between helicobacter pylori eradication therapy and gut microbiota dysbiosis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(04): 359-363.
[11]	Wanyong Zhu, Le Wang, Yue Xu, Xinjun Wang, Chen Ye, Ning Li, Qiyi Chen, Long Li. Gut microbiota dysbiosis and functional intestinal disorders：from mechanistic insights to fecal microbiota transplantation therapy [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(02): 142-147.
[12]	Changjia Yu, Yiting Zhang, Gaole Zhang, Chenguang Li. Research progress of gut microbiome and ploysaccharids in chronic constipation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(02): 166-173.
[13]	Yangyang Xiao, Jiaqu Cui, Zuoxi Huang, Jian Li, Chuanwen Liao. Research progress of gut microbiota in radiation enteritis and its treatment [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(02): 174-178.
[14]	Yulin Wang, Zhonghua Wang, Ziwen Liu, Mengxin Lyu, Yuanzi Yu, Tao Li, Jinhua Hu, Xiaoqian Zhang. Metagenomics analysis of intestinal microbiota in patients with liver cirrhotic gastrointestinal bleeding before and after transjugular intrahepatic portosystemic shunt [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(02): 135-143.
[15]	Yuan Sun, Zhenyu Jiang, Yi Zhou, Chi Wang, Hongsuo Chen. To explore the relationship between chronic pancreatitis and intestinal microbiota [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2025, 12(02): 114-121.

Please choose a citation manager

Content to export